INAHTA — LLMpedia

INAHTA
Name	INAHTA
Formation	1993
Type	International network
Headquarters	International
Region served	Global
Membership	Health technology assessment agencies

Contents

INAHTA

The International Network of Agencies for Health Technology Assessment is a global association connecting health assessment bodies and public World Health Organization partners across Europe, North America, Asia, South America, Africa and Oceania. Founded amid policy debates involving Organization for Economic Co-operation and Development delegates and European Union health advisers, INAHTA fostered links among national agencies such as National Institute for Health and Care Excellence, Canadian Agency for Drugs and Technologies in Health, Swedish Agency for Health Technology Assessment, and provincial bodies like Institut national d'excellence en santé et en services sociaux affiliates. The network works with international programs including Coordinating Committee for Multilateral Export Controls, Global Fund to Fight AIDS, Tuberculosis and Malaria, Bill & Melinda Gates Foundation, and research institutions such as Harvard Medical School, Imperial College London, Johns Hopkins University and McMaster University.

History

INAHTA emerged from meetings involving representatives from National Health Service executives, Government of Canada policy units, and European health ministries in the early 1990s, paralleling initiatives by World Bank analysts and Organisation for Economic Co-operation and Development health committees. Early contributors included leaders from Scottish Intercollegiate Guidelines Network, Institut national de la santé et de la recherche médicale, and the German Institute for Quality and Efficiency in Health Care. Founding activities aligned with projects funded by European Commission directorates and collaborations with Pan American Health Organization offices. Over time INAHTA convened with stakeholders from United Nations, Gavi, the Vaccine Alliance, Asian Development Bank, African Union health divisions, and national ministries such as Department of Health and Social Care and Ministry of Health (Brazil).

INAHTA’s remit coordinates assessments that inform decision makers in bodies like European Medicines Agency, Food and Drug Administration, Health Canada, Australian Department of Health, and subnational agencies such as Basque Health Service. Its functions include methodological harmonization with standards from Cochrane Collaboration, GRADE Working Group, and guidance referenced by World Health Organization committees. INAHTA supports capacity-building with partners including World Bank, UNICEF, United Nations Development Programme, and academic centers like London School of Hygiene & Tropical Medicine and Karolinska Institutet. It advocates evidence use alongside systems such as EUnetHTA, Health Technology Assessment International, and networks linked to European Observatory on Health Systems and Policies.

INAHTA members conduct assessments on pharmaceuticals evaluated by European Medicines Agency and Food and Drug Administration, medical devices reviewed in contexts like International Medical Device Regulators Forum, diagnostics relevant to Centers for Disease Control and Prevention guidance, and public health interventions considered by World Health Organization emergency committees. Assessments use methods developed in collaboration with Cochrane Collaboration, GRADE Working Group, Agency for Healthcare Research and Quality, and meta-analysis teams from Cochrane Central. Members have examined innovations linked to projects supported by Bill & Melinda Gates Foundation, Gavi, the Vaccine Alliance, and trials registered with ClinicalTrials.gov and ISRCTN. Topics include cost-effectiveness models used in National Institute for Health and Care Excellence appraisals, comparative effectiveness studies analogous to those by Institute for Clinical and Economic Review, and health system impact analyses paralleling European Observatory on Health Systems and Policies reports.

Collaborative outputs appear in reports similar to those by Health Technology Assessment (journal), briefs used by European Commission consultations, and syntheses shared with World Health Organization guideline panels. Projects have included methodological guides reminiscent of work by Cochrane Collaboration and training modules delivered with London School of Hygiene & Tropical Medicine, University of Toronto, McMaster University and University of Melbourne. INAHTA-affiliated agencies have published assessments influencing reimbursement decisions made by bodies like National Health Service trusts, Health Canada, Australian Pharmaceutical Benefits Advisory Committee, and regional payers such as Sécurité sociale (France). Collaborative initiatives often involve funders and partners such as Wellcome Trust, European Commission Horizon 2020, and International Development Research Centre.

Critiques mirror concerns raised for entities like World Health Organization and European Medicines Agency regarding transparency, timeliness, and conflicts of interest when interacting with industry actors including Pfizer, Roche, Novartis, GlaxoSmithKline, and Johnson & Johnson. Challenges include harmonizing methods across diverse systems such as National Institute for Health and Care Excellence appraisal frameworks, resource constraints comparable to those faced by Health Technology Assessment International members, and responding rapidly during crises similar to responses by Centers for Disease Control and Prevention and European Centre for Disease Prevention and Control. Future debates involve interactions with regulatory pathways like those of European Medicines Agency, coverage decisions by payers such as Medicare (United States), and integration with evidence syntheses from groups like Cochrane Collaboration.

Category:Health technology assessment